by MM360 Staff | Mar 10, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Mar 9, 2026 | Myeloma News
Treatment with the targeted therapy Venclexta (venetoclax) in combination with chemotherapy led to disease remission for most people with hard-to-treat acute myeloid leukemia (AML) in an early clinical trial, with most patients able to undergo stem cell transplant...
by MM360 Staff | Mar 8, 2026 | Publications
Eur J Nucl Med Mol Imaging. 2026 Mar 7. doi: 10.1007/s00259-026-07830-5. Online ahead of print. NO ABSTRACT PMID:41792563 | DOI:10.1007/s00259-026-07830-5
by MM360 Staff | Mar 7, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Matthew Shinkle | Mar 6, 2026 | Uncategorized
The FDA has approved teclistamab-cqyv in combination with daratumumab hyaluronidase-fihj for adults with relapsed or refractory multiple myeloma who received at least one prior line of therapy.As the third approval under the Commissioner’s National Priority Voucher...
